Anupam Rasayan India Limited
Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries.
What Anupam files
- Others71
- Investor Meet34
- Updates30
- Board Meeting15
- PPTs10
- Important9
Anupam Rasayan will acquire up to 74.20% control of Bliss GVS Pharma for ~Rs. 1369.51 Cr (initial stake) plus ~Rs. 829.03 Cr (open offer). This strengthens ARIL's pharma value chain presence, adding niche products and global reach for synergistic growth.
Anupam Rasayan secured a $30 million External Commercial Borrowing from Axis Bank and syndicated lenders. This loan, secured by company assets, will partially fund the acquisition of Monitchem Kansas S.à r.l., supporting strategic growth.
Anupam Rasayan acquired Doriath (100% subsidiary) and 15% of Batam. To fund Doriath's Monitchem Kansas acquisition, it secured USD 20 million credit. ARIL also raised USD 30 million via ECB and guarantees total USD 150 million for subsidiary facilities, securing with its assets.
Anupam Rasayan acquires Monitchem Kansas and its subsidiaries, including Jayhawk Fine Chemicals, for up to USD 155 million cash. This 100% control acquisition strengthens US manufacturing, adds niche capabilities, and expands its American customer base in specialty chemicals.
Anupam Rasayan launched 'Saksham Niveshak', a 100-day campaign for shareholders to update KYC & claim unpaid dividends. This prevents dividends and underlying shares from being transferred to a fund. Investors should contact the RTA for updates.